In C57/BL6 nude mouse pancreatic cancer xenograft models, researchers found that treatment with allicin alone or in combination with recombinant interleukin-2 could inhibit the progression of pancreatic tumors, and they found that the combination treatment could significantly inhibit the growth of xenografts and prolong the survival time through the activation of CD4 T, CD8 T, and NK cells (Wang et al., 2013). The gene discussed is CD4; the disease is pancreatic neoplasm.